Advertisement
Table 3 societal costs associated with ranibizumab therapy for neovascular age-related macular degeneration
| Parameter | Cost |
|---|---|
| Direct ophthalmic medical costs | |
| Ranibizumab therapy (81.3% bilateral) | $79,056 |
| Direct non-ophthalmic medical costs | |
| Injury reduction | (−$664) |
| Depression reduction | (−$2543) |
| SNF cost decrease | (−$4100) |
| Unexplained medical cost decrease | (−$28,598) |
| Nursing home | (−$19,069) |
| Total offsetting costs | (−$54,974) |
| Total direct medical costs | $24,082 |
| Direct non-medical costs | |
| Paid caregiver salariesa | (−$82,419) |
| Salary gain for freed-up caregivers now able to take up gainful employment | (−$215,123) |
| Total direct non-medical costs | (−$297,542) |
| Indirect medical costs | |
| Mean patient wage gain | (−$9057) |
| Total societal costs | (−$282,517) |
